Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.59 |
| ▸ | TERT | O14746 | 3/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099563 | 0.96 | FOLH1 (0.56) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL29670883 | 0.95 | FOLH1 (0.59) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL29655322 | 0.93 | FOLH1 (0.52) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL1370320 | 0.93 | FOLH1 (0.58) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL1370325 | 0.93 | FOLH1 (0.58) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL2887200 | 0.92 | TERT (0.52) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL2887196 | 0.92 | TERT (0.52) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL30099692 | 0.91 | FOLH1 (0.56) | FOLH1TERTNOD1SLC6A5PTGS1 | |
| SCHEMBL30785838 | 0.91 | FOLH1 (0.48) | FOLH1TERTNOD1SLC6A5GSR | |
| SCHEMBL29915442 | 0.89 | TERT (0.50) | FOLH1TERTNOD1SLC6A5GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162959-B2 | Cyclic peptide for treating cancer | SAINT LEO UNIVERSITY (US) | 2024-12-10 | — | — | US | claimed |
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025096630-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4543480-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | Sustain Holdings, LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119698289-A | Pharmaceutical composition based on collagen peptide and application thereof | 莎思坦控股有限责任公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12162959-B2 | Cyclic peptide for treating cancer | SAINT LEO UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240016900-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC | 2024-01-18 | — | — | US | disclosed |
| WO-2024006771-A2 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | SUSTAIN HOLDINGS, LLC (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115261-A1 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND USES THEREOF | COL1A1, COL2A1, COL14A1 | FOLH1 1961/4885TERT 2188/4885NOD1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.